Hypersensitivity reactions associated with oxaliplatin and their clinical management

Bibliography

• Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007;7(8):573-84
   PubMed Web of Science ®Google Scholar
• Kim GP, Erlichman C. Oxaliplatin in the treatment of colorectal cancer. Expert Opin Drug Metab Toxicol 2007;3(2):281-94
   PubMed Web of Science ®Google Scholar
• Grothey A, Goldberg RM. A review of oxaliplatin and its clinical use in colorectal cancer. Expert Opin Pharmacother 2004;5(10):2159-70
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I, Weber B, Cretin J, et al. Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group. Br J Cancer 2009;100(4):601-7
   PubMed Web of Science ®Google Scholar
• Lorgis V, Chauffert B, Gentil J, et al. Influence of localization of primary tumor on effectiveness of 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma: a retrospective study. Anticancer Res 2012;32(9):4125-30
   PubMed Web of Science ®Google Scholar
• Muggia FM. Recent updates in the clinical use of platinum compounds for the treatment of gynecologic cancers. Semin Oncol 2004;31(6 Suppl 14):17-24
   PubMed Web of Science ®Google Scholar
• Maindrault-Goebel F, Andre T, Tournigand C, et al. Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients. Eur J Cancer 2005;41(15):2262-7
   PubMed Web of Science ®Google Scholar
• Hewitt MR, Sun W. Oxaliplatin-associated hypersensitivity reactions: clinical presentation and management. Clin Colorectal Cancer 2006;6(2):114-17
   PubMed Web of Science ®Google Scholar
• Shepherd GM. Hypersensitivity reactions to chemotherapeutic drugs. Clin Rev Allergy Immunol 2003;24(3):253-62
   PubMed Web of Science ®Google Scholar
• Shao YY, Hu FC, Liang JT, et al. Characteristics and risk factors of oxaliplatin-related hypersensitivity reactions. J Formos Med Assoc 2010;109(5):362-8
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Cancer facts and figures. American Cancer Society; Atlanta: 2009
   Google Scholar
• Eloxatin (oxaliplatin injection). Sanofi Aventis US, Bridgewater NJ; 2007. Available from: www.eloxatin.com or http://products.sanofi.us/eloxatin/eloxatin.html [Last accessed May 2014]
   Google Scholar
• Brandi G, Pantaleo MA, Galli C, et al. Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer 2003;89(3):477-81
   PubMed Web of Science ®Google Scholar
• Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350(23):2343-51
   PubMed Web of Science ®Google Scholar
• Kim BH, Bradley T, Tai J, et al. Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review. Oncology 2009;76(4):231-8
   PubMed Web of Science ®Google Scholar
• Seki K, Senzaki K, Tsuduki Y, et al. Risk factors for oxaliplatin-induced hypersensitivity reactions in Japanese patients with advanced colorectal cancer. Int J Med Sci 2011;8(3):210-15
   PubMed Web of Science ®Google Scholar
• Suenaga M, Mizunuma N, Shinozaki E, et al. Management of allergic reactions to oxaliplatin in colorectal cancer patients. J Support Oncol 2008;6(8):373-8
   PubMedGoogle Scholar
• Siu SW, Chan RT, Au GK. Hypersensitivity reactions to oxaliplatin: experience in a single institute. Ann Oncol 2006;17(2):259-61
   PubMed Web of Science ®Google Scholar
• Ichikawa Y, Goto A, Hirokawa S, et al. Allergic reactions to oxaliplatin in a single institute in Japan. Jpn J Clin Oncol 2009;39(9):616-20
   PubMed Web of Science ®Google Scholar
• Kim MY, Kang SY, Lee SY, et al. Hypersensitivity reactions to oxaliplatin: clinical features and risk factors in Koreans. Asian Pac J Cancer Prev 2012;13(4):1209-15
   PubMed Web of Science ®Google Scholar
• Parel M, Ranchon F, Nosbaum A, et al. Hypersensitivity to oxaliplatin: clinical features and risk factors. BMC Pharmacol Toxicol 2014;15:1
   PubMed Web of Science ®Google Scholar
• Thomas RR, Quinn MG, Schuler B, et al. Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer 2003;97(9):2301-7
   PubMed Web of Science ®Google Scholar
• Lee MY, Yang MH, Liu JH, et al. Severe anaphylactic reactions in patients receiving oxaliplatin therapy: a rare but potentially fatal complication. Support Care Cancer 2007;15(1):89-93
   PubMed Web of Science ®Google Scholar
• Misset JL. Oxaliplatin in practice. Br J Cancer 1998;77(Suppl 4):4-7
   PubMedGoogle Scholar
• Lee SY, Kang HR, Song WJ, et al. Overcoming oxaliplatin hypersensitivity: different strategies are needed according to the severity and previous exposure. Cancer Chemother Pharmacol 2014;73(5):1021-9
   PubMed Web of Science ®Google Scholar
• Polyzos A, Tsavaris N, Gogas H, et al. Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience. Oncology 2009;76(1):36-41
   PubMed Web of Science ®Google Scholar
• Medioni J, Coulon MA, Morere JF, et al. Anaphylaxis after oxaliplatin. Ann Oncol 1999;10(5):610
   PubMedGoogle Scholar
• Saif M, Roy S, Ledbetter L, et al. Fever as the only manifestation of hypersensitivity reactions associated with oxaliplatin in a patient with colorectal cancer Oxaliplatin-induced hypersensitivity reaction. World J Gastroenterol 2007;13(39):5277-81
   PubMed Web of Science ®Google Scholar
• Madrigal-Burgaleta R, Berges-Gimeno MP, Angel-Pereira D, et al. Desensitizing oxaliplatin-induced fever: a case report. J Investig Allergol Clin Immunol 2013;23(6):435-6
   PubMed Web of Science ®Google Scholar
• Earle CC, Chen WY, Ryan DP, et al. Oxaliplatin-induced Evan’s syndrome. Br J Cancer 2001;84(3):441
   PubMed Web of Science ®Google Scholar
• Sorbye H, Bruserud Y, Dahl O. Oxaliplatin-induced haematological emergency with an immediate severe thrombocytopenia and haemolysis. Acta Oncol 2001;40(7):882-3
   PubMed Web of Science ®Google Scholar
• Dold FG, Mitchell EP. Sudden-onset thrombocytopenia with oxaliplatin. Ann Intern Med 2003;139(2):E156
   PubMedGoogle Scholar
• Koutras AK, Makatsoris T, Paliogianni F, et al. Oxaliplatin-induced acute-onset thrombocytopenia, hemorrhage and hemolysis. Oncology 2004;67(2):179-82
   PubMed Web of Science ®Google Scholar
• Taleghani BM, Meyer O, Fontana S, et al. Oxaliplatin-induced immune pancytopenia. Transfusion 2005;45(5):704-8
   PubMed Web of Science ®Google Scholar
• Curtis BR, Kaliszewski J, Marques MB, et al. Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin. Am J Hematol 2006;81(3):193-8
   PubMed Web of Science ®Google Scholar
• Pavic M, Moncharmont P, Seve P, et al. Oxaliplatin-induced immune thrombocytopenia. Gastroenterol Clin Biol 2006;30(5):797-8
   PubMedGoogle Scholar
• Shao YY, Hong RL. Fatal thrombocytopenia after oxaliplatin-based chemotherapy. Anticancer Res 2008;28(5B):3115-17
   PubMed Web of Science ®Google Scholar
• Gell PHG, Coombs RRA. Clinical aspects of immunology. Blackwell Science; Oxford, UK: 1975
   Google Scholar
• Syrigou E, Syrigos K, Saif MW. Hypersensitivity reactions to oxaliplatin and other antineoplastic agents. Curr Allergy Asthma Rep 2008;8(1):56-62
   PubMed Web of Science ®Google Scholar
• Santini D, Tonini G, Salerno A, et al. Idiosyncratic reaction after oxaliplatin infusion. Ann Oncol 2001;12(1):132-3
   PubMed Web of Science ®Google Scholar
• Tonini G, Santini D, Vincenzi B, et al. Oxaliplatin may induce cytokine-release syndrome in colorectal cancer patients. J Biol Regul Homeost Agents 2002;16(2):105-9
   PubMed Web of Science ®Google Scholar
• Ulrich-Pur H, Penz M, Fiebiger WC, et al. Oxaliplatin-induced fever and release of IL-6. Oncology 2000;59(3):187-9
   PubMed Web of Science ®Google Scholar
• Garufi C, Vaglio S, Brienza S, et al. Immunohemolytic anemia following oxaliplatin administration. Ann Oncol 2000;11(4):497
   PubMed Web of Science ®Google Scholar
• Forcello NP, Khubchandani S, Patel SJ, et al. Oxaliplatin-induced immune-mediated cytopenias: a case report and literature review. J Oncol Pharm Pract 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Saif MW, The A, Ledbetter L. Oxaliplatin-mediated autoimmune thrombocytopenia. Clin Colorectal Cancer 2009;8(1):61-2
   PubMed Web of Science ®Google Scholar
• Masse MS, Caimmi D, Demoly P. A delayed reaction to oxaliplatin. J Investig Allergol Clin Immunol 2012;22(5):372-3
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Masaki T, Kogawa K, et al. Hemoptysis and acute respiratory syndrome (ARDS) as delayed-type hypersensitivity after FOLFOX4 plus bevacizumab treatment. Int Surg 2013;98(4):445-9
   PubMed Web of Science ®Google Scholar
• Newman Taylor AJ, Cullinan P, Lympany PA, et al. Interaction of HLA phenotype and exposure intensity in sensitization to complex platinum salts. Am J Respir Crit Care Med 1999;160(2):435-8
   PubMed Web of Science ®Google Scholar
• Mori Y, Nishimura T, Kitano T, et al. Oxaliplatin-free interval as a risk factor for hypersensitivity reaction among colorectal cancer patients treated with FOLFOX. Oncology 2010;79(1-2):136-43
   PubMed Web of Science ®Google Scholar
• Shibata Y, Ariyama H, Baba E, et al. Oxaliplatin-induced allergic reaction in patients with colorectal cancer in Japan. Int J Clin Oncol 2009;14(5):397-401
   PubMed Web of Science ®Google Scholar
• Pagani M, Bonadonna P, Senna GE, et al. Standardization of skin tests for diagnosis and prevention of hypersensitivity reactions to oxaliplatin. Int Arch Allergy Immunol 2008;145(1):54-7
   PubMed Web of Science ®Google Scholar
• Garufi C, Cristaudo A, Vanni B, et al. Skin testing and hypersensitivity reactions to oxaliplatin. Ann Oncol 2003;14(3):497-8
   PubMed Web of Science ®Google Scholar
• Meyer L, Zuberbier T, Worm M, et al. Hypersensitivity reactions to oxaliplatin: cross-reactivity to carboplatin and the introduction of a desensitization schedule. J Clin Oncol 2002;20(4):1146-7
   PubMed Web of Science ®Google Scholar
• Leguy-Seguin V, Jolimoy G, Coudert B, et al. Diagnostic and predictive value of skin testing in platinum salt hypersensitivity. J Allergy Clin Immunol 2007;119(3):726-30
   PubMed Web of Science ®Google Scholar
• Pagani M, Bonadonna P. Skin test protocol for the prevention of hypersensitivity reactions to oxaliplatin. Anticancer Res 2014;34(1):537-40
   PubMed Web of Science ®Google Scholar
• Zanotti KM, Markman M. Prevention and management of antineoplastic-induced hypersensitivity reactions. Drug Saf 2001;24(10):767-79
   PubMed Web of Science ®Google Scholar
• Madrigal-Burgaleta R, Berges-Gimeno MP, Angel-Pereira D, et al. Hypersensitivity and desensitization to antineoplastic agents: outcomes of 189 procedures with a new short protocol and novel diagnostic tools assessment. Allergy 2013;68(7):853-61
   PubMed Web of Science ®Google Scholar
• Kidera Y, Satoh T, Ueda S, et al. High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin. Int J Clin Oncol 2011;16(3):244-9
   PubMed Web of Science ®Google Scholar
• Lee SY, Kim MY, Kim MH, et al. Hypersensitivity reactions to oxaliplatin: outcomes of premedication and desensitization. J Allergy Clin Immunol 2013;131(2 Suppl):AB166
   Web of Science ®Google Scholar
• Bhargava P, Gammon D, McCormick MJ. Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer 2004;100(1):211-12
   PubMed Web of Science ®Google Scholar
• Park SJ, Lee KY, Park WS, et al. Clinical outcomes of reintroducing oxaliplatin to patients with colorectal cancer after mild hypersensitivity reactions. Oncology 2013;85(6):323-7
   PubMed Web of Science ®Google Scholar
• Castells M, Sancho-Serra Mdel C, Simarro M. Hypersensitivity to antineoplastic agents: mechanisms and treatment with rapid desensitization. Cancer Immunol Immunother 2012;61(9):1575-84
   PubMed Web of Science ®Google Scholar
• Cortijo-Cascajares S, Nacle-Lopez I, Garcia-Escobar I, et al. Effectiveness of oxaliplatin desensitization protocols. Clin Transl Oncol 2013;15(3):219-25
   PubMed Web of Science ®Google Scholar
• Castells MC, Tennant NM, Sloane DE, et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 2008;122(3):574-80
   PubMed Web of Science ®Google Scholar
• Nozawa H, Muto Y, Yamada Y. Desensitization to oxaliplatin with two stages of premedication in a patient with metastatic rectal cancer. Clin Ther 2008;30(6):1160-5
   PubMed Web of Science ®Google Scholar
• Syrigou EI, Karapanagiotou EM, Alamara CV, et al. Hypersensitivity reactions to oxaliplatin: a retrospective study and the development of a desensitization protocol. Clin Colorectal Cancer 2009;8(2):106-9
   Web of Science ®Google Scholar
• Lim KH, Huang MJ, Lin HC, et al. Hypersensitivity reactions to oxaliplatin: a case report and the success of a continuous infusional desensitization schedule. Anticancer Drugs 2004;15(6):605-7
   PubMed Web of Science ®Google Scholar
• Schull B, Kornek GV, Scheithauer W. Idiosyncratic reaction after oxaliplatin: circumvention by use of a continuous infusional administration schedule. Ann Oncol 2001;12(11):1653-4
   PubMed Web of Science ®Google Scholar
• Herrero T, Tornero P, Infante S, et al. Diagnosis and management of hypersensitivity reactions caused by oxaliplatin. J Investig Allergol Clin Immunol 2006;16(5):327-30
   PubMed Web of Science ®Google Scholar
• Updegraff A, Doshi DR. Clinical experience with oxaliplatin (O) desensitization (OD): a case series. J Allergy Clin Immunol 2014;133(2 Suppl):AB269
   Web of Science ®Google Scholar
• Gamelin L, Boisdron-Celle M, Delva R, et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 2004;10(12 Pt 1):4055-61
   PubMed Web of Science ®Google Scholar
• Saif MW, Reardon J. Management of oxaliplatin-induced peripheral neuropathy. Ther Clin Risk Manag 2005;1(4):249-58
   PubMedGoogle Scholar
• Knijn N, Tol J, Koopman M, et al. The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients. Eur J Cancer 2011;47(3):369-74
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Qin R, Dakhil SR, et al. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol 2014;32(10):997-1005
   PubMed Web of Science ®Google Scholar
• Wrzesinski SH, McGurk ML, Donovan CT, et al. Successful desensitization to oxaliplatin with incorporation of calcium gluconate and magnesium sulfate. Anticancer Drugs 2007;18(6):721-4
   PubMed Web of Science ®Google Scholar
• Wong JT, Ling M, Patil S, et al. Oxaliplatin hypersensitivity: evaluation, implications of skin testing, and desensitization. J Allergy Clin Immunol Pract 2014;2(1):40-5
   Google Scholar
• Caiado J, Venemalm L, Pereira-Santos MC, et al. Carboplatin-, oxaliplatin-, and cisplatin-specific IgE: cross-reactivity and value in the diagnosis of carboplatin and oxaliplatin allergy. J Allergy Clin Immunol Pract 2013;1(5):494-500
   Google Scholar
• Breslow RG, Caiado J, Castells MC. Acetylsalicylic acid and montelukast block mast cell mediator-related symptoms during rapid desensitization. Ann Allergy Asthma Immunol 2009;102(2):155-60
   PubMed Web of Science ®Google Scholar
• André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009;27(19):3109-16
   PubMed Web of Science ®Google Scholar
• Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22(1):23-30
   PubMed Web of Science ®Google Scholar
• Ramanathan RK, Clark JW, Kemeny NE, et al. Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer. J Clin Oncol 2003;21(15):2904-11
   PubMed Web of Science ®Google Scholar